Bellus Medical was featured in the October 2018 issue of Practical Dermatology due to our recent acquisition by Crown Laboratories. Here’s the basic story:
“Bellus’ non-invasive offerings include the SkinPen®, a medical grade microneedling device used exclusively by healthcare professionals to improve the appearance of facial acne scars. It is the first microneedling device to be granted clearance and marketing authorization by the FDA or this indication.”
Other Bellus products include:
- Skinfuse®: post-microneedling protocol
- Allumera®: light-activated cream
- ProGen™ and RegenLab®: platelet-rich plasma systems
“Bellus will become the new Aesthetics Division of Crown Laboratories and will be renamed Bellus Aesthetics. Bellus will continue to be based in Dallas and operate as a wholly owned subsidiary of Crown Laboratories. Bellus CEO Joe Proctor will become president of Crown’s Aesthetics Division and join the Crown Board of Directors.”
Read the full story here.